InflaRx N.V.
General ticker "IFRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $98.8M (TTM average)
InflaRx N.V. follows the US Stock Market performance with the rate: 54.2%.
Estimated limits based on current volatility of 4.6%: low 1.40$, high 1.53$
Factors to consider:
- Total employees count: 65 (-12.2%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.77$, 2.16$]
- 2026-12-31 to 2027-12-31 estimated range: [0.76$, 2.08$]
Financial Metrics affecting the IFRX estimates:
- Positive: with PPE of -1.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 5.07 > 2.08
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Operating cash flow
- Positive: Interest expense per share per price, % of 0.06 <= 0.07
- Positive: 69.38 < Shareholder equity ratio, % of 75.26 <= 81.92
Short-term IFRX quotes
Long-term IFRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €0.06MM | €0.17MM | €0.03MM |
| Operating Expenses | €44.66MM | €53.07MM | €48.29MM |
| Operating Income | €-44.59MM | €-52.91MM | €-48.26MM |
| Non-Operating Income | €1.93MM | €6.85MM | €2.64MM |
| Interest Expense | €0.04MM | €0.02MM | €0.04MM |
| R&D Expense | €41.02MM | €35.36MM | €25.72MM |
| Income(Loss) | €-42.67MM | €-46.06MM | €-45.62MM |
| Taxes | €0.00MM | €0.01MM | €0.01MM |
| Net Income(Loss)* | €-42.67MM | €-46.06MM | €-45.63MM |
| Stockholders Equity | €102.58MM | €61.42MM | €41.54MM |
| Inventory | €11.37MM | €6.90MM | €0.00MM |
| Assets | €120.21MM | €76.02MM | €55.19MM |
| Operating Cash Flow | €-37.81MM | €-48.56MM | €-33.92MM |
| Capital expenditure | €0.08MM | €0.05MM | €0.11MM |
| Investing Cash Flow | €-17.70MM | €52.36MM | €3.11MM |
| Financing Cash Flow | €52.99MM | €0.39MM | €32.00MM |
| Earnings Per Share** | €-0.78 | €-0.78 | €-0.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.